Sanofi granted Thomson Reuters Extel Survey award

The 2012 Thomson Reuters Extel Survey Awards were announced today, with Sanofi, the French multinational pharmaceutical company headquartered in Paris, being granted the award for "Leading Pan-European Quoted Company for Investor Relations." Considered the leading benchmark for excellence in Investor Relations (IR), the survey highlights achievement across companies listed in Europe.

For the third consecutive year, Sanofi was also voted first in the European Pharmaceuticals & Biotechnology sector and first among CAC 40 companies. Since being voted in to the Top 100 Pan-European Quoted Companies for IR in 2009, where Sanofi ranked 35th, the company has continued to rise up the list, finishing in 5th place in 2010, and ranking 2nd last year.

"Investor Relations is a strategic management responsibility which ultimately contributes to a company's enhanced stock value in the long term. As the Extel IR rankings now get votes for over 1,500 quoted companies, to be first in Pan-Europe is a true accolade and recognition from investors and analysts," commented Steve Kelly, Managing Director, Extel with Thomson Reuters.

The 2012 Extel Survey looked back on the contribution of over 14,000 professionals from over 2,100 buyside firms, more than 2,500 analysts from 270 brokerage firms/research houses and nearly 800 of Europe's largest quoted companies worldwide throughout 2012.

Christopher A. Viehbacher, Chief Executive Officer, Sanofi, said, "This Extel award is a fantastic achievement for Sanofi and reflects the considerable efforts by management and the Investor Relations team to actively engage with the financial community. We thank investors and analysts for their votes."

For more information on Sanofi market research, see the latest report: Sanofi Market Research

Follow us on Twitter @CandMResearch